BFM
PBYI icon

Boothbay Fund Management’s Puma Biotechnology PBYI Stock Holding History

Boothbay Fund Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-265
Closed -$1.57M – 911
2018
Q2 		$1.57M Buy
+265
New +$15.4K 0.14% 123

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Boothbay Fund Management's PBYI Position: Q1 2024 in Review

Boothbay Fund Management sold out of Puma Biotechnology (PBYI) in Q1 2024, closing a stake of 17,895 shares — an estimated $77.5K sold.

Boothbay Fund Management first reported a position in PBYI in Q3 2019 and held it in 11 quarters. The position peaked at $695K in Q3 2019. 93 funds tracked by Wall St. Rank hold PBYI as of Q1 2024.

  • Boothbay Fund Management reported no remaining Puma Biotechnology position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 17,895 Puma Biotechnology shares in Q1 2024, an estimated $77.5K.
  • Boothbay Fund Management first reported a position in Puma Biotechnology in Q3 2019 and held it in 11 quarters.
  • Boothbay Fund Management's Puma Biotechnology position peaked at $695K in Q3 2019.
  • 93 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.